Tizanidine Tablet
Product Images NDC 68788-4159

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 68788-4159). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 01)

Chemical structure of tizanidine hydrochloride, showing its molecular framework with chlorine, nitrogen, sulfur atoms, and the hydrochloride component.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 02)

A line graph showing plasma tizanidine concentration (ng/mL) over time (hours) after dosing. The graph compares 4 mg tizanidine tablets and capsules taken with and without food, displaying concentration peaks and decline from 0 to 24 hours post-dose.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 03)

Line graph depicting improvement in Ashworth Score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis shows improvement score and the x-axis shows hours post-dose up to 6 hours. The 16 mg dose shows the greatest improvement, followed by 8 mg, with placebo showing minimal change.*

FDA Label Image

Image (356b3e79 D47b 467a Af62 2adca35f1a2f 04)

A line graph comparing improvement in Ashworth score across three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint with last observation carried forward. Two groups are shown: tizanidine (mean dose 28.8 mg) represented by squares and placebo represented by circles with error bars indicating variability.*

FDA Label Image

Tizanidine Hydrochloride Tablet 4mg (356b3e79 D47b 467a Af62 2adca35f1a2f 06)

Label for tizanidine hydrochloride tablets 4 mg by Preferred Pharmaceuticals Inc. The label states it is a generic for Zanaflex, with each tablet containing 4.576 mg tizanidine HCl equivalent to 4 mg base. Manufactured by Graviti Pharmaceuticals Pvt. Ltd. Includes warnings about storage and drowsiness, plus dosage instructions in English and Spanish. Contains barcodes and spaces for lot, batch, expiration date, and NDC information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.